UK firm Trimtech emerges with $31M seed round for TRIM21 bispecifics

March 7, 2025

Trimtech Therapeutics closed a £25 million (US$31 million) oversubscribed seed funding round to advance its targeted protein degradation treatments for neurodegenerative and inflammatory diseases.

BioWorld Science Financings Inflammatory Neurology/psychiatric Bispecific antibody Seed Europe

Today's news in brief

BioWorld

BioWorld briefs for March 25, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 25, 2025

Lost in trans-lation? Trump’s mouse charge doesn’t click

BioWorld

U.S. President Donald Trump touched off a not-uncommon flurry of puzzlement and outrage when, during his speech to Congress on March 4, he referred to an example...

Gene therapy efforts active, despite low Bluebird, 2seventy bids

BioWorld

Bristol Myers Squibb Co.’s decision this week to snag Bluebird Bio Inc. spinout 2seventy Bio Inc. for $102 million net – just weeks after investors bid $30...

US NIH grant peer review to get a bit of a makeover

BioWorld

Looking to shave $65 million from its annual expenditures while streamlining the first stage of its two-level grant review process, the U.S. NIH is proposing to...